Observational Study
Copyright ©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Diabetes. Aug 15, 2023; 14(8): 1280-1288
Published online Aug 15, 2023. doi: 10.4239/wjd.v14.i8.1280
Effects of glucagon-like peptide-1 receptor agonists on glucose excursion and inflammation in overweight or obese type 2 diabetic patients
Xiao-Min Huang, Xing Zhong, Yi-Jun Du, Yan-Yun Guo, Tian-Rong Pan
Xiao-Min Huang, Xing Zhong, Yi-Jun Du, Yan-Yun Guo, Tian-Rong Pan, Department of Endocrinology, The Second Affiliated Hospital of Anhui Medical University, Hefei 230601, Anhui Province, China
Author contributions: Pan TR took part in the study coordination; Huang XM took part in the study execution, data collection, and discussions; Zhong X, Du YJ, Guo YY, and Pan TR took part in the study design, supervision, and drafting of the manuscript; Zhong X, Du YJ, and Guo YY contributed to the data analyses.
Supported by the Clinical Research and Cultivation Plan Project of the Second Affiliated Hospital of Anhui Medical University, No. 2021LCYB17.
Institutional review board statement: The study was reviewed and approved by the Ethics Committee of the Second Affiliated Hospital of Anhui Medical University (Approval No. YX2019-055).
Informed consent statement: All study participants provided informed written consent prior to study enrolment.
Conflict-of-interest statement: The authors have no conflicts of interest to declare.
Data sharing statement: No additional data are available.
STROBE statement: The authors have read the STROBE Statement-checklist of items, and the manuscript was prepared and revised according to the STROBE Statement-checklist of items.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Tian-Rong Pan, MD, Chief Physician, Department of Endocrinology, The Second Affiliated Hospital of Anhui Medical University, No. 678 Furong Road, Economic and Technological Development Zone, Hefei 230601, Anhui Province, China. ptr1968@163.com
Received: April 19, 2023
Peer-review started: April 19, 2023
First decision: April 28, 2023
Revised: May 16, 2023
Accepted: June 21, 2023
Article in press: June 21, 2023
Published online: August 15, 2023
Processing time: 114 Days and 2.6 Hours
Core Tip

Core Tip: Weekly formulation of glucagon-like peptide-1 receptor agonists (GLP-1RAs) exhibited superior efficacy in treating obese patients with type 2 diabetes mellitus compared to the daily formulation. It effectively controls blood glucose levels, better regulates blood lipids, inhibits inflammatory reactions, and reduces adverse reactions. Therefore, the weekly formulation of GLP-1RA is a promising treatment option worthy of clinical promotion.